CD8+ T cells are end effectors of cancer immunity. Most forms of effective cancer
immunotherapy involve CD8+ T cell effector function. Here, we review the current …

Tissue localization is a critical determinant of T cell immunity. CD8+ T cells are contact-
dependent killers, which requires them to physically be within the tissue of interest to kill …

Background Stereotactic ablative radiotherapy (SABR) is the standard treatment for
medically inoperable early-stage non-small-cell lung cancer (NSCLC), but regional or …

Abstract Immune-checkpoint inhibitors (ICBs), in addition to targeting CTLA-4, PD-1, and PD-
L1, novel targeting LAG-3 drugs have also been approved in clinical application. With the …

T cells can acquire a broad spectrum of differentiation states following activation. At the
extreme ends of this continuum are short-lived cells equipped with effector machinery and …

Head and neck tumors (HNTs) constitute a multifaceted ensemble of pathologies that
primarily involve regions such as the oral cavity, pharynx, and nasal cavity. The intricate …

Lymph nodes (LNs) are important hubs for metastatic cell arrest and growth, immune
modulation, and secondary dissemination to distant sites through a series of mechanisms …

Thirty years of foundational research investigating molecular and cellular mechanisms
promoting T cell exhaustion are now enabling rational design of T cell–based therapies for …

The coordination of immunity across organs is fundamental to cancer development and
progression. It is well known that the hostile metabolic microenvironment in the tumour is a …

The immune checkpoint blockade (ICB) response in human cancers is closely linked to the
gut microbiota. Here, we report that the abundance of commensal Lactobacillus johnsonii is …